Skip to main content
. Author manuscript; available in PMC: 2014 Sep 9.
Published in final edited form as: Adv Funct Mater. 2013 Feb 6;23(24):3040–3052. doi: 10.1002/adfm.201202215

Figure 5. PAT-SPN cytocompatibility across a range of N(+)/P(-) ratios assessed on luciferase-expressing R221A-Luc tumor cells.

Figure 5

Cell viability was assessed by treating luciferase expressing R221A-Luc mammary tumor cells with PAT-SPNs loaded with 50 nM scrambled siRNA at N(+)/P(-) ratio of 2:1, 4:1, 6:1, 8:1, and 12:1 in the presence of MMP (50 nM) and supplemented with Zn2+ (50 μM) (MMP+Zn). Cell viability was reported relative to non-treated cells (NT). Significant cytotoxicity was observed relative to NT at a charge ratio of 12:1 (58 ± 9% viability) but not at lower charge ratios. Data presented as mean +/- standard error with n=3 from three independent experiments. *p<0.05 compared with NT.